摘要
目的探讨鞘内药物输注系统(intrathecal drug delivery system,IDDS)植入技术在癌性疼痛患者中的治疗效果、相关并发症及治疗体会。方法回顾分析中国科学技术大学附属第一医院(安徽省立医院)神经外科自2024年1月至2025年3月5例接受鞘内药物输注系统植入癌性疼痛患者的临床资料、治疗方案并复习相关文献。结果5例患者中有4例采用鞘内药物输注系统植入(全植入)技术,1例采用鞘内药物输注系统植入(半植入-输液港)技术,术后患者疼痛视觉模拟评分(visual analogue scale,VAS)平均由术前的9.4分下降至3.2分,巴罗神经病学研究所(Barrow Neurological institute,BNI)疼痛评分由术前Ⅴ级下降至Ⅱ级,疼痛缓解效果满意。结论鞘内药物输注系统植入技术在癌性疼痛中的应用镇痛疗效确切,不良反应小,可以作为癌性疼痛的治疗手段。
Objective To investigate the therapeutic efficacy,complications,and clinical insights of intrathecal drug delivery system(IDDS)implantation in cancer pain patients.Methods A retrospective analysis was conducted on 5 cancer pain patients who underwent IDDS implantation at the Department of Neurosurgery,The First Affiliated Hospital of USTC(Anhui Provincial Hospital)from January 2024 to March 2025.Clinical data,treatment,and relevant literature were reviewed.Results Among the 5 cases,4 received fully implanted IDDS,while 1 underwent semi-implanted(port-catheter)IDDS.Postoperatively,the average visual analogue scale(VAS)score decreased from 9.4 to 3.2,and the Barrow Neurological Institute(BNI)pain intensity score improved from grade V to II,demonstrating significant pain relief.Conclusion IDDS implantation is an effective and low-adverse-effect intervention for cancer pain management,serving as a viable therapeutic option.
作者
李政
江彦
牛朝诗
梅加明
Li Zheng;Jiang Yan;Niu Chaoshi;Mei Jiaming(Department of Neurosurgery,the First Affiliated Hospital of University of Science and Technology of China,Anhui Provincial Hospital,Hefei,230001,China)
出处
《立体定向和功能性神经外科杂志》
2025年第5期284-288,294,共6页
Chinese Journal of Stereotactic and Functional Neurosurgery
基金
安徽省高等学校科学研究项目(编号:2024AH052051)。
关键词
鞘内药物输注系统
癌性疼痛
吗啡
Intrathecal drug delivery system
Cancer pain
Morphine
